Depression, Bipolar
45
11
13
21
Key Insights
Highlights
Success Rate
95% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 17/100
2.2%
1 terminated out of 45 trials
95.5%
+8.9% vs benchmark
33%
15 trials in Phase 3/4
43%
9 of 21 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 21 completed trials
Clinical Trials (45)
Acceptability & Safety of Two Sequential Doses of Psilocybin in Bipolar Disorder II Depression and Suicidality
Natural History of Depression, Bipolar Disorder and Suicide Risk
Longitudinal Study on the Sustainability of Transcranial Magnetic Stimulation Protocols - Biomarkers
Dallas 2K: A Natural History Study of Depression
IM Ketamine vs Midazolam for Suicidal ER Patients
Lithium Versus Cariprazine in the Acute Phase Treatment of Bipolar Depression (DUAG9)
Right-sided 1-Hz Repetitive Transcranial Magnetic Stimulation (rTMS) Versus Left-sided Intermittent Theta Burst Stimulation (iTBS) in Patients With Depression
Pramipexole to Target "Anhedonic Depression"
Precision Subclassification of Mental Health in Diabetes: Digital Twins for Precision Mental Health to Track Subgroups
Mental Health Mission Mood Disorder Cohort Study
Digital Phenotypes for Predicting Depression
Transcranial Direct Current Stimulation Therapy for Bipolar Depression
Optimal Electrical Stimulus During Electroconvulsive Therapy
BioClock: Bright Light Therapy for Depressive Disorders
Long Term Follow-up of Deep Brain Stimulation for Treatment-Resistant Depression
A Study of Abilify® Tablet(Aripiprazole) as an Adjunctive Treatment in the Bipolar Depression
Light-Therapy in the Treatment of the Acute Phase of the Bipolar Type II Depression
LIVES: Personalized Lifestyle Intervention for Patients With Depression
Study of the Effectiveness of Vestibular Stimulation Treatment in the Depressive Phase of Bipolar Disorder
Study of a Vestibular Biomarker of Phase in Bipolar Disorder